We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

PH:NYSEParker-Hannifin Corporation Analysis

Data as of 2026-04-24 - not real-time

$974.47

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Parker‑Hannifin (PH) is trading at $974.47, comfortably above its 20‑day SMA of $949.41 and 50‑day SMA of $954.46, indicating short‑term price strength. The MACD line sits at 11.76 above its signal at 9.83, delivering an bullish histogram of 1.93, while the 14‑day RSI at 55 suggests neutral momentum with room to rise. Volatility remains elevated at 32% over the past 30 days, yet the beta of ~1.0 points to market‑aligned risk. The Fear & Greed Index at 88 (“Extreme Greed”) reflects strong investor appetite.
Fundamentally, PH posted 9.1% revenue growth and a healthy operating margin of 21.7%, supporting a forward PE of 28.6 versus the industry average of 31.1, though the current PE of 35.6 signals a premium valuation. The dividend has been raised 11% to $2.00 per share, yielding 0.74% with a modest payout ratio of 26%, underscoring sustainability. A DCF‑derived fair value of $313 implies the stock is materially overvalued, yet analyst consensus targets a median price of $1,070, suggesting an upside of roughly 6% from the current level. Recent news of the board’s dividend increase and continued acquisitions bolsters confidence, while notable insider selling introduces a cautionary note. Overall, the blend of solid cash flow, disciplined capital allocation, and favorable industrial tailwinds supports a positive outlook.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 7/10

Key Factors

  • Bullish MACD crossover
  • Price above short‑term SMAs
  • Sustainable dividend

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Revenue and margin expansion
  • Analyst target upside
  • Strategic acquisitions

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • Strong cash flow generation
  • Industry cyclicality risk
  • Valuation premium

Key Metrics & Analysis

Financial Health

Revenue Growth9.10%
Profit Margin17.29%
P/E Ratio35.6
ROE25.78%
ROA9.44%
Debt/Equity68.92
P/B Ratio8.6
Op. Cash Flow$3.7B
Free Cash Flow$2.5B
Industry P/E31.1

Technical Analysis

TrendNeutral
RSI55.1
Support$858.72
Resistance$1,029.00
MA 20$949.41
MA 50$954.46
MA 200$847.13
MACDBullish
VolumeStable
Fear & Greed Index88.02

Valuation

Fair Value$312.96
Target Price$1,034.83
Upside/Downside6.19%
GradeOvervalued
TypeGrowth
Dividend Yield0.74%

Risk Assessment

Beta1.02
Volatility32.24%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.